Processing thermally labile drugs by hot-melt extrusion: The lesson with gliclazide

被引:73
作者
Huang, Siyuan [1 ,2 ]
O'Donnell, Kevin P. [3 ]
de Vaux, Sophie M. Delpon [1 ]
O'Brien, John [4 ]
Stutzman, John [4 ]
William, Robert O., III [1 ]
机构
[1] Univ Texas Austin, Coll Pharm, Div Pharmaceut, 2409 Univ Ave,Mail Stop A1920, Austin, TX 78712 USA
[2] Eli Lilly & Co, Lilly Res Labs, Small Mol Design & Dev, Indianapolis, IN 46285 USA
[3] Dow Chem Co USA, Dow Food Pharma & Med, Midland, MI 48674 USA
[4] Dow Chem Co USA, Analyt Sci, Midland, MI 48674 USA
关键词
Melt extrusion; Process optimization; AFFINISOL HPMC HME; Solid dispersion; Degradation; Arrhenius kinetics; Amorphous; AMORPHOUS SOLID DISPERSIONS; PROCESS PARAMETERS; DISSOLUTION ENHANCEMENT; CHEMICAL DEGRADATION; FORCED DEGRADATION; SOLUBLE DRUG; STABILITY; ITRACONAZOLE; FORMULATION; HYDROLYSIS;
D O I
10.1016/j.ejpb.2017.05.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The formation of molecularly dispersed amorphous solid dispersions by the hot-melt extrusion technique relies on the thermal and mechanical energy inputs, which can cause chemical degradation of drugs and polymeric carriers. Additionally, drug degradation may be exacerbated as drugs convert from a more stable crystalline form to a higher energy amorphous form. Therefore, it is imperative to study how drug degrades and evaluate methods to minimize drug degradation during the extrusion process. In this work, gliclazide was used as a model, thermally labile drug for the degradation kinetics and process optimization studies. Preformulation studies were conducted using thermal analyses, and liquid chromatography mass spectroscopy to identify drug degradation pathways and to determine initial extrusion conditions. Formulations containing 10% drug and 90% AFFINISOL (TM) HPMC HME 100LV were then extruded using a twin screw extruder, and the extrudates were characterized using X-ray powder diffraction, modulated dynamic scanning calorimetry, and potency testing to evaluate physicochemical properties. The energies of activation for both amorphous gliclazide, crystalline gliclazide, and gliclazide solution were calculated using the Arrhenius equation to further guide the extrusion optimization process. Preformulation studies identify two hydrolysis degradation pathways of gliclazide at elevated temperatures. The activation energy study indicates a significantly higher degradation rate for the amorphous gliclazide compared to the crystalline form. After optimization of the hot-melt extrusion process, including improved screw designs, machine setup, and processing conditions, gliclazide amorphous solid dispersion with similar to 95% drug recovery was achieved. The ability to process thermally labile drugs and polymers using hot-melt extrusion will significantly expand the possible applications of this manufacturing process. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 67
页数:12
相关论文
共 59 条
[1]   Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 1: Predicting Degradation Related Impurities and Impurity Considerations for Pharmaceutical Dosage Forms [J].
Alsante, Karen M. ;
Huynh-Ba, Kim ;
Baertschi, Steven W. ;
Reed, Robert A. ;
Landis, Margaret S. ;
Kleinman, Mark H. ;
Foti, Christopher ;
Rao, Venkatramana M. ;
Meers, Paul ;
Abend, Andreas ;
Reynolds, Daniel W. ;
Joshi, Biren K. .
AAPS PHARMSCITECH, 2014, 15 (01) :198-212
[2]   Characterization of mass ionizable degradation products of gliclazide by LC/ESI-MS [J].
Bansal, Gulshan ;
Singh, Manjeet ;
Jindal, K. C. ;
Singh, Saranjit .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2008, 31 (14) :2174-2193
[3]   Forced degradation study on gliclazide and application of validated stability-indicating HPLC-UV method in stability testing of gliclazide tablets [J].
Bansal, Gulshan ;
Singh, Manjeet ;
Jindal, Kaur Chand .
CHROMATOGRAPHIA, 2007, 66 (9-10) :751-755
[4]   Process design and control of a twin screw hot melt extrusion for continuous pharmaceutical tamper-resistant tablet production [J].
Baronsky-Probst, J. ;
Moeltgen, C. -V. ;
Kessler, W. ;
Kessler, R. W. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 87 :14-21
[5]  
Berndl G., 2013, US Patent, Patent No. [8,486,456, 8486456]
[6]  
Blessy M, 2014, J Pharm Anal, V4, P159, DOI 10.1016/j.jpha.2013.09.003
[7]   Melt extrusion: from process to drug delivery technology [J].
Breitenbach, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2002, 54 (02) :107-117
[8]   Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery [J].
Brough, Chris ;
Williams, R. O., III .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 453 (01) :157-166
[9]   Pharmaceutical applications of hot-melt extrusion: Part I [J].
Crowley, Michael M. ;
Zhang, Feng ;
Repka, Michael A. ;
Thumma, Sridhar ;
Upadhye, Sampada B. ;
Battu, Sunil Kumar ;
McGinity, James W. ;
Martin, Charles .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (09) :909-926
[10]  
DellaValle G, 1995, CARBOHYD POLYM, V28, P255, DOI 10.1016/0144-8617(95)00111-5